| 2 | The state-of-the-arts of the study on grid interconnection between Iberian Peninsula and West Maghreb region显示文摘With the change of energy structure in Europe and the trend of diversification of energy supply, the interconnection of the power grid in the Mediterranean region has gradually become a hotspot in European energy research. This paper introduces the power supply, load demand, power grid construction and the present situation of multinational interregional interconnection in the Iberian Peninsula of the Tour of Mediterranean in Europe(Portugal and Spain) and the Western Maghreb countries(Morocco and Algeria). And the driving force and influence factors of regional power grid interconnection are also analyzed. According to the MEDGRID project aimed at realizing the Mediterranean power grid interconnection, this paper presents the interconnection schemes of the Iberian Peninsula and the Western Maghreb. Furthermore, the subsequent technical problems need to be solved are also expounded. | Hong Shen Qian Dai Qi Wu Junling Wu Qinyong Zhou Jiarong Wang Wei Yang Rui Pestana Ricardo Pastor | 2018 | Global Energy Interconnection2018，1，1： | 0 |
| 3 | Dendritic cell vaccination in glioblastoma after fluorescenceguided resection显示文摘AIM: To assess whether the addition of a customized, active immunotherapy to standard of care including fluorescence-guided surgery, may provide hints of an improved survival for patients with poor-prognosis, incurable glioblastoma multiform. METHODS: Preliminary to our ongoing, phase-Ⅱ clinical trial, we conducted a small pilot study enrolling five consecutive patients with resectable glioblastoma. In terms of Recursive Partitioning Analysis, four patientswere class Ⅴ and one was class Ⅳ. In all five cases, fluorescence-guided surgery was employed, followed by rapid steroid discontinuation. Patients were then treated with a combination of standard radio-chemotherapy with temozolomide and tumor lysate-pulsed, mature dendritic cell-based vaccinations.RESULTS: Though all five patients ultimately progressed, with any further treatment left to the sole decision of the treating oncologist, active immunotherapy was very well tolerated and induced specific immune responses in all three patients for whom enough material was available for such an assessment. Median progression-free survival was 16.1 mo. Even more important, median and mean overall survival were 27 mo and 26 mo, respectively. Three patients have died with an overall survival of 9 mo, 27 mo and 27.4 mo, while the other two are still alive at 32 mo and 36 mo, the former receiving treatment with bevacizumab, while the latter has now been off therapy for 12 mo. Four of five patients were alive at two years.CONCLUSION: Active immunotherapy with tumor lysate-pulsed, autologous dendritic cells is feasible, safe, well tolerated and biologically efficacious. A phase-Ⅱ study is ongoing to possibly improve further on our very encouraging clinical results. | Ricardo Diez Valle Ascension Lopez-Diaz de Cerio Susana Inoges Sonia Tejada Fernando Pastor Helena Villanueva Jaime Gallego Jaime Espinos Javier Aristu Miguel Angel Idoate Enrique Andreu Maurizio Bendandi | 2012 | World Journal of Clinical Oncology2012，3，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员